Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Net Margin (2016 - 2025)

Historic Net Margin for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to 209.83%.

  • ImmunityBio's Net Margin rose 11945600.0% to 209.83% in Q3 2025 from the same period last year, while for Sep 2025 it was 422.41%, marking a year-over-year increase of 75955900.0%. This contributed to the annual value of 2805.32% for FY2024, which is 910615600.0% up from last year.
  • ImmunityBio's Net Margin amounted to 209.83% in Q3 2025, which was up 11945600.0% from 350.44% recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Net Margin registered a high of 209.83% during Q3 2025, and its lowest value of 735700.0% during Q1 2022.
  • Moreover, its 5-year median value for Net Margin was 57900.0% (2021), whereas its average is 131407.41%.
  • As far as peak fluctuations go, ImmunityBio's Net Margin crashed by 2000000000bps in 2022, and later skyrocketed by 2000000000bps in 2023.
  • Quarter analysis of 5 years shows ImmunityBio's Net Margin stood at 23475.13% in 2021, then tumbled by -532bps to 148391.78% in 2022, then decreased by -13bps to 167923.74% in 2023, then surged by 100bps to 783.62% in 2024, then skyrocketed by 73bps to 209.83% in 2025.
  • Its Net Margin stands at 209.83% for Q3 2025, versus 350.44% for Q2 2025 and 785.05% for Q1 2025.